Jarvis
  • CATEGORIES
    • Equity Markets
    • Investing Basics
    • AI for investing
    • Trending Stock Market News: Quick Reads
    • Portfolio Management
    • Stock Market News Updates
    • Global Stock Market
    • Stock Advisory
  • I AM A
    • Beginner
    • Intermediate
  • Home
  • Products
    • Jarvis Portfolio
    • Jarvis Protect
    • Jarvis OneStock
    • Jarvis Prime – For HNIs & UHNIs
    • Jarvis Sentiment Tracker – AI Tool for F&O
    • Jarvis US Multi-Asset Portfolio
    • Jarvis Atlas
  • FAQs
  • About Us
  • Contact Us
  • Become a Partner
No Result
View All Result
Jarvis
  • CATEGORIES
    • Equity Markets
    • Investing Basics
    • AI for investing
    • Trending Stock Market News: Quick Reads
    • Portfolio Management
    • Stock Market News Updates
    • Global Stock Market
    • Stock Advisory
  • I AM A
    • Beginner
    • Intermediate
  • Home
  • Products
    • Jarvis Portfolio
    • Jarvis Protect
    • Jarvis OneStock
    • Jarvis Prime – For HNIs & UHNIs
    • Jarvis Sentiment Tracker – AI Tool for F&O
    • Jarvis US Multi-Asset Portfolio
    • Jarvis Atlas
  • FAQs
  • About Us
  • Contact Us
  • Become a Partner
No Result
View All Result
Jarvis
No Result
View All Result
Home Stock Market News Updates

Friday, 16th April 2021

by Sumit Chanda
April 16, 2021
in Stock Market News Updates
Reading Time: 4 mins read
A A
0
Share on FacebookShare on Twitter

Wipro reported 27.8% higher net profit of Rs.2,972 crore for the Mar-21 quarter, on the back of better operating margins during the quarter. However, the sequential profits were almost flat. Revenues were up just 3.4% at Rs.16,245 crore, largely driven by growth in the European markets. The numbers were in line with street expectations. Operating margins expanded by 340 bps on a yoy basis at over 21%. Wipro has given revenue growth guidance of 2-4%, excluding the recent Capco and Ampion acquisitions.

Indian exports for the month of March 2021 jumped 60.3% to $34.45 billion, on the back of an Agri-export push. However, outbound shipments for the full fiscal year 2020-21 contracted 7.26% to $290.63 billion. The import growth also kept pace growing 53.3% to $48.38 billion for the month of March 2021. However, for the full fiscal FY21, the total imports were lower by 18% at $389.18 billion. The actual trade deficit widened to $13.93 billion in Mar-21 but full-year trade deficit for FY21 was down 39% at $98.56 billion.

On Thursday, the stock market indices staged a smart recovery in the last hour of trade as the rally was led by private sector banks, metals and pharma stocks. The Sensex closed 260 points higher at 48,804, still short of its psychological 50,000 levels. This is commendable since the index had touched a day-low of 48,010 after India reported a record spike of over 2 lakh cases on Wednesday. While short covering was the story in private banks and metals, there was value buying in pharma stocks. FMCG stocks slipped.

Eicher Motors slipped 4% to touch a 3-month low of Rs.2,384 on Thursday. Analysts are becoming cautious about the prospects of the company; both in terms of volumes and price. There is also a fear that the sharp spike in the price of commodities may have to be partly absorbed by Eicher on account of the extremely competitive situation in the market. The two-wheeler space is not only vulnerable to supply shocks but also to fuel prices. Nomura has warned that EV disruption cannot entirely be ruled out.

Sugar stocks rallied 9-10% on Thursday 15 April on expectations of better earnings growth in Q4. This is likely to be driven by the subsidy announced in December 2020 which has resulted in a strong momentum in sugar exports. Most of the sugar companies like Balrampur Chini, Uttam Sugar, Dalmia Bharat, Dhampur, EID Parry and Dwarikesh Sugar rallied sharply during the day. In addition, the government has been aggressive about taking ethanol blending in petrol to 20% by 2025 and that favours sugar stocks.

One of the oldest foreign banks in India, Citigroup, will shutter its retail banking operations in 13 nations including India and China. Citi, apparently, does not find the consumer / retail operations profitable to run in India in the light of the growing heft of Indian banks. Apart from India and China; Citi will also pull out of Australia, Bahrain, Indonesia, Korea, and a few more. However, Citi institutional business will continue to be serviced in these geographies. Citi believes that it lacks the requisite scale to operate these markets. 

Aurobindo Pharma plans to demerge its injectables business and could seek board approval shortly. The entire demerger process is expected to be completed in FY22. The main objective of this plan is to unlock value as injectables account for 20% of its total revenues. The injectables business is expected to double its revenues to $700 billion in the next 3 years. For example, injectables trade at an average P/E of 30X while Aurobindo trades at a P/E of just 14X. Aurobindo may also look at this kind of plan for Biosimilars.

SBI has clarified on media reports pertaining to the excess charges levied by SBI and other banks on zero-balance accounts. It is estimated that SBI collected Rs.300 crore plus from such BSBDA accounts via extra charges in the last 5 years. SBI has clarified that RBI regulations permit banks to levy charges for beyond 4 free transactions on BSBD accounts. SBI also underscored that effective Sep-20, it stopped charging for any digital transaction but levied charges on more than 4 cash withdrawals. SBI has also waived SMS fees.

Sumit Chanda

Sumit Chanda

Sumit has 18 years of experience in BFSI industry, into devising strategy for various functions, Investments and Managing Asset Portfolios. Specializes in Strategy & implementation in sales & operations, Team management, IT implementation, Affiliations.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Jarvis Invest

India's AI-powered, SEBI-registered investment advisory — research, portfolios and global market intelligence for every investor.

Company

  • About Us
  • FAQs
  • Contact Us
  • Become a Partner

Products

  • Jarvis Portfolio
  • Jarvis Protect
  • Jarvis OneStock
  • Jarvis Prime
  • Sentiment Tracker (F&O)
  • US Multi-Asset Portfolio

Explore Topics

  • Equity Markets
  • Investing Basics
  • AI for investing
  • Trending Stock Market News: Quick Reads
  • Financial Planning
  • Portfolio Management
  • Stock Market News Updates
  • Global Stock Market

Get in touch

Customer support customersupport@jarvisinvest.com

Jarvis Invest — SEBI Registered Investment Adviser (Reg. No. INA000013235) & SEBI Registered Research Analyst (Reg. No. INH000018762). Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

© 2026 Jarvis Invest. All rights reserved.

  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
Categories
Equity MarketsGet latest insights on the Indian equity market including stock trends, market analysis, sector…Investing BasicsLearn stock market basics including investing fundamentals, equity concepts, and beginner-friendly guides to start…AI for investingStay ahead with AI-powered stock insights, trend analysis, and intelligent investing strategies for ai…Trending Stock Market News: Quick ReadsDiscover the latest trends in the stock market with insightful blogs from Jarvis Invest…Portfolio ManagementExpert insights on portfolio management, asset allocation, risk management, and strategies to optimise best…Stock Market News UpdatesGet daily stock market news updates, key market movements, and insights that matter to…Global Stock MarketGet latest global stock market news, trends, and AI-driven stock insights on US, Europe…Stock AdvisoryLearn how AI-powered stock advisory and expert market research can help you build wealth.
I Am A
BeginnerBeginner-friendly stock market guides covering investing basics, common mistakes, and simple strategies to build…IntermediateIntermediate-level stock market insights covering investment strategies, portfolio analysis, and market concepts for informed…
Products
Jarvis PortfolioModel portfolio matched to your risk profile for long-term wealth creation.Jarvis ProtectContinuous portfolio monitoring for your existing portfolio with timely sell alerts to help manage downside risk.Jarvis OneStockHigh-conviction stock recommendations designed for short-term investing.Jarvis Prime - For HNIs & UHNIsPremium portfolio management services for investors with ₹25 lakh+ investment corpus.Jarvis Sentiment Tracker - AI Tool for F&OReal-time market sentiment analysis and trading signals for options traders.Jarvis US Multi-Asset PortfolioDiversified US portfolio investing across stocks and ETFs with automated portfolio management.Jarvis AtlasInvestment opportunities across Indian equities, global markets, and commodities in 10+ global markets.
No Result
View All Result
  • CATEGORIES
    • Equity Markets
    • Investing Basics
    • AI for investing
    • Trending Stock Market News: Quick Reads
    • Portfolio Management
    • Stock Market News Updates
    • Global Stock Market
    • Stock Advisory
  • I AM A
    • Beginner
    • Intermediate
  • Home
  • Products
    • Jarvis Portfolio
    • Jarvis Protect
    • Jarvis OneStock
    • Jarvis Prime – For HNIs & UHNIs
    • Jarvis Sentiment Tracker – AI Tool for F&O
    • Jarvis US Multi-Asset Portfolio
    • Jarvis Atlas
  • FAQs
  • About Us
  • Contact Us
  • Become a Partner

© 2023 Jarvis Invest

Go to mobile version